Squarepoint
DNLI icon

Squarepoint’s Denali Therapeutics DNLI Stock Holding History

Squarepoint’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-80,518
Closed -$1.17M – 4395
2025
Q3 		$1.17M Buy
+80,518
New +$1.16M ﹤0.01% 2558
2025
Q2 		– Sell
-687,151
Closed -$9.34M – 4609
2025
Q1 		$9.34M Buy
687,151
+638,532
+1,313% +$12.2M 0.01% 1062
2024
Q4 		$991K Buy
48,619
+14,896
+44% +$381K ﹤0.01% 3078
2024
Q3 		$982K Sell
33,723
-89,957
-73% -$2.23M ﹤0.01% 2619
2024
Q2 		$2.87M Buy
123,680
+58,806
+91% +$1.13M ﹤0.01% 1780
2024
Q1 		$1.33M Buy
64,874
+50,555
+353% +$950K ﹤0.01% 2368
2023
Q4 		$307K Sell
14,319
-95,750
-87% -$1.9M ﹤0.01% 3337
2023
Q3 		$2.27M Buy
+110,069
New +$2.79M 0.01% 1715
2023
Q2 		– Sell
-235,662
Closed -$5.43M – 3652
2023
Q1 		$5.43M Buy
+235,662
New +$6.49M 0.02% 839
2022
Q4 		– Sell
-13,365
Closed -$410K – 3255
2022
Q3 		$410K Buy
+13,365
New +$435K ﹤0.01% 2300
2022
Q2 		– Sell
-34,435
Closed -$1.11M – 2981
2022
Q1 		$1.11M Buy
+34,435
New +$1.18M ﹤0.01% 1530
2021
Q4 		– Sell
-17,200
Closed -$868K – 3229
2021
Q3 		$868K Sell
17,200
-1,150
-6% -$64.8K ﹤0.01% 1644
2021
Q2 		$1.44M Buy
18,350
+13,022
+244% +$806K 0.01% 1379
2021
Q1 		$304K Buy
+5,328
New +$357K ﹤0.01% 2383
2020
Q4 		– Sell
-14,411
Closed -$516K – 2985
2020
Q3 		$516K Buy
+14,411
New +$434K 0.01% 1410
2019
Q4 		– Sell
-18,657
Closed -$286K – 2540
2019
Q3 		$286K Sell
18,657
-12,279
-40% -$235K ﹤0.01% 1927
2019
Q2 		$642K Sell
30,936
-74,204
-71% -$1.66M 0.01% 1522
2019
Q1 		$2.44M Buy
+105,140
New +$2.2M 0.03% 695

Other funds holding DNLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Squarepoint's DNLI Position: Q4 2025 in Review

Squarepoint sold out of Denali Therapeutics (DNLI) in Q4 2025, closing a stake of 80,518 shares — an estimated $1.17M sold.

Squarepoint first reported a position in DNLI in Q1 2019 and held it in 18 quarters. The position peaked at $9.34M in Q1 2025. 250 funds tracked by Wall St. Rank hold DNLI as of Q4 2025.

  • Squarepoint reported no remaining Denali Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Squarepoint sold 80,518 Denali Therapeutics shares in Q4 2025, an estimated $1.17M.
  • Squarepoint first reported a position in Denali Therapeutics in Q1 2019 and held it in 18 quarters.
  • Squarepoint's Denali Therapeutics position peaked at $9.34M in Q1 2025.
  • 250 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2025.

Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.